
Chemistry - A European Journal p. 17397 - 17406 (2016)
Update date:2022-08-16
Topics:
Jerhaoui, Soufyan
Chahdoura, Faouzi
Rose, Clémence
Djukic, Jean-Pierre
Wencel-Delord, Joanna
Colobert, Fran?oise
An original and recyclable chiral bidentate aniline-sulfoxide-based directing group has been developed. This auxiliary allows challenging stereoselective Pd-catalyzed direct functionalization of small cycloalkanes through C–aryl and C–alkyl bond formation. Although moderate diastereoselectivities are observed, both optically pure enantiomers of the highly functionalized products can be obtained separately by simple silica gel chromatography and cleavage of the chiral auxiliary. This strategy was further applied to the preparation of enantiomerically pure 1,2,3-trisubstituted cyclopropane carboxylic acid derivatives, with three stereogenic centers and bearing both alkyl and aromatic substituents. These molecular scaffolds are not yet reported in the literature. The synthetic utility of this approach is validated by the chiral auxiliary being readily cleaved and recovered posteriori to the C?H activation step, without deterioration of its optical purity. Finally, an unprecedented palladacycle intermediate generated through C?H activation of the cyclopropane moiety has been isolated and fully characterized. Initial DFT calculations shed additional light on the reactivity of this original intermediate.
View More
Contact:0833-5590788/5590338/5590055
Address:Victory in the town of Red Star Village,Mount Emei City,industrial concentration area storage processing logistics parkpark
Zhejiang Rongkai Chemical Technology Co.,Ltd.
Contact:+86-578-8185786
Address:Shangjiang Industrial Zone,Suichang
Cangzhou Senary Chemical Science-tech Co., Ltd
Contact:+86-317-3563899, 3563699
Address:168 Jinde Road, Cangzhou, Hebei, China
chengdu firsterchem Pharmaceutical Co., Ltd.
Contact:028-66825849
Address:chengdu
Shanghai Sunway Pharmaceutical Technology Co.,Ltd.
Contact:+86-21-5161 3915
Address:Shanghai YangPu
Doi:10.1021/acs.organomet.1c00171
(2021)Doi:10.1016/j.jallcom.2020.155879
(2020)Doi:10.1021/acs.molpharmaceut.8b01196
(2019)Doi:10.1246/bcsj.53.1471
(1980)Doi:10.1002/anie.200601432
(2006)Doi:10.1016/j.tet.2011.01.025
(2011)